Champions Oncology, Inc.
CSBR
$7.05
-$0.02-0.28%
NASDAQ
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.43% | 13.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.43% | 13.27% | |||
| Cost of Revenue | -9.17% | 9.96% | |||
| Gross Profit | 29.55% | 18.02% | |||
| SG&A Expenses | 12.36% | -8.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.40% | 3.08% | |||
| Operating Income | 136.49% | 70.42% | |||
| Income Before Tax | 156.42% | 76.99% | |||
| Income Tax Expenses | 28.57% | 110.85% | |||
| Earnings from Continuing Operations | 150.86% | 74.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 3.33% | -- | |||
| Net Income | 161.47% | 76.24% | |||
| EBIT | 136.49% | 70.42% | |||
| EBITDA | 463.76% | 88.71% | |||
| EPS Basic | 161.39% | 76.31% | |||
| Normalized Basic EPS | 179.31% | 77.08% | |||
| EPS Diluted | 161.39% | 76.31% | |||
| Normalized Diluted EPS | 175.86% | 77.08% | |||
| Average Basic Shares Outstanding | 0.03% | 0.25% | |||
| Average Diluted Shares Outstanding | 4.85% | 0.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||